VESL (Virtual Engagement Social Learning) is an online learning community for Canadian healthcare professionals with an interest in atherosclerotic cardiovascular disease.
VESL has been created to sustain a connection amongst Canadian clinicians and researchers, to exchange clinical findings and professional perspectives, promoting the highest level of care for patients in Canada.
Members of the VESL community will receive a weekly email digest with curated articles from sources identified by the VESL faculty as well as periodic learning oppotunities including online discussions and polls, podcasts and webinars
LegitiMed will be managing this virtual community residing on Sosido (www.sosido.com).
If you are interested in participating in VESL, please contact email@example.com.
Thank you to Novartis Canada for their financial support of this initiative.
The VESL community is designed for the scientific exchange of information between Healthcare Professionals and is made possible with financial support from Novartis Canada. Novartis does not itself monitor the discussions. However a third-party service provider does review the discussions only for the purpose of identifying any potential adverse event (AE) discussion. This review is required since as a drug manufacturer, Novartis has a regulatory obligation to report any AE that (directly or indirectly) comes to their attention. The third-party will only report the potential AE discussion and will include contact information. Should your post be reported to patient safety, you will be contacted by the third-party service provider to determine if you would like Novartis patient safety to contact you for more details.